LB Pharmaceuticals Inc Common Stock
NASDAQ:LBRXBiotechnology
-$0.39 today
- Market cap
- $1.30B
- Beta
- 0.71
- P/E (TTM)
- -21.4
- EPS (TTM)
- -$1.39
Volume 0.40M
Average 0.23M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
LB Pharmaceuticals Inc Common Stock
NASDAQ:LBRX
Intrinsic Alpha fair value
Locked
Current Price
$40.30
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | N/A2 analysts |
| Net Income | N/A | N/A | N/A | N/A2 analysts |
| EBIT | N/A | N/A | N/A | N/A2 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
Definium Therapeutics, Inc. NASDAQ:DFTX | $4.39B | $32.08 | Not rated | -11.0 | +157.49% |
ACADIA Pharmaceuticals Inc. NASDAQ:ACAD | $3.24B | $18.75 | Undervalued | 9.7 | -23.03% |
Denali Therapeutics Inc. NASDAQ:DNLI | $3.00B | $18.74 | Not rated | -8.7 | +2.97% |
GH Research PLC NASDAQ:GHRS | $1.31B | $19.10 | Not rated | -23.8 | +32.87% |
Rapport Therapeutics, Inc. Common Stock NASDAQ:RAPP | $1.25B | $26.15 | Not rated | -16.2 | -6.16% |
Alto Neuroscience, Inc. NYSE:ANRO | $1.18B | $29.54 | Not rated | -9.8 | +68.88% |
Seaport Therapeutics, Inc. Common Stock NASDAQ:SPTX | $1.07B | $19.98 | Not rated | — | — |
MapLight Therapeutics, Inc. NASDAQ:MPLT | $308.98M | $7.25 | Not rated | -2.8 | -55.82% |
Minerva Neurosciences, Inc. NASDAQ:NERV | $114.62M | $2.30 | Not rated | -0.2 | -49.77% |
Neumora Therapeutics, Inc. Common Stock NASDAQ:NMRA | $80.59M | $0.43 | Not rated | -1.2 | -87.42% |
Continue the stock analysis
Jump to another research area for this company.